GlaxoSmithKline (GSK) Receiving Somewhat Favorable News Coverage, Report Finds
News stories about GlaxoSmithKline (NYSE:GSK) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the pharmaceutical company an impact score of 46.5028977923105 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Is It Time To Sell GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) Based Off Its PE Ratio? (finance.yahoo.com)
- Reading the Estimates for Novartis’s Alcon in 4Q17 (finance.yahoo.com)
- Novartis on the Street: Analyst Ratings and Recommendations (finance.yahoo.com)
- Drug companies told to do more to tackle ‘superbug’ crisis (finance.yahoo.com)
- FTSE 100 steady, but pound pain persists (marketwatch.com)
GlaxoSmithKline (GSK) traded up $0.13 during trading on Tuesday, reaching $38.69. 3,545,085 shares of the company’s stock were exchanged, compared to its average volume of 5,599,883. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline has a 52 week low of $34.52 and a 52 week high of $44.53. The firm has a market cap of $93,370.00, a P/E ratio of 29.09, a PEG ratio of 2.37 and a beta of 0.97.
The firm also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were given a dividend of $0.5037 per share. The ex-dividend date of this dividend was Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a yield of 5.21%. GlaxoSmithKline’s dividend payout ratio is presently 153.38%.
A number of equities research analysts have commented on GSK shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 18th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Wednesday, October 18th. Bank of America lowered shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Investec lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of $38.57.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.